Q4 FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 10, 2026
ImageneBio, Inc. (IMA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $136.2 million in cash and investments and $1.9 million in total debt.
Revenue
$0
-100.0% vs prior quarter
Net income
$-10.18M
-34.2% vs year-ago quarter
Operating cash flow
$-9.07M
+23.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.63
+85.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
11.35M
-76.5% vs year-ago quarter
Net cash
$134.24M
Q2 FY2026
Operating margin
-3324.2%
Q3 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1835579
- Former names
- Ikena Oncology, Inc. (until Jul 25, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $800,000 | $0 |
| Operating income | -$11.8M | -$12.1M | -$8.5M | -$26.6M | -$7.4M |
| Net income | -$10.2M | -$10.6M | -$6.9M | -$24.8M | -$7.6M |
| Diluted EPS | -$0.63 | -$0.95 | — | -$2.91 | -$4.46 |
| Operating cash flow | -$9.1M | -$14.8M | -$7.2M | -$21.5M | -$11.9M |
| Total assets | $152.0M | $136.7M | $153.0M | $160.9M | $126.2M |
| Total liabilities | $10.0M | $13.4M | $19.8M | $21.0M | $10.3M |
| Stockholders' equity | $142.1M | $123.3M | $133.1M | $139.8M | -$180.4M |
| Cash and investments | $136.2M | $117.2M | $135.3M | $142.6M | $95.6M |
| Total debt | $1.9M | $2.4M | $3.0M | $3.4M | $5.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 23, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 26, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 336 ImageneBio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.